Posted by Michael Wonder on 05 May 2024
Vyndamax (tafamidis) PBS listed for adult patients with wild type or hereditary transthyretin amyloid cardiomyopathy with New York Heart Association class I-II heart failure
4 May 2024 - The availability of Vyndamax on the PBS provides subsidised access to a once daily oral single capsule treatment for transthyretin amyloid cardiomyopathy for adults with New York Heart Association class I-II heart failure.
Pfizer Australia has welcomed the announcement that Vyndamax (tafamidis), which is approved in Australia for adult patients with wild type or hereditary transthyretin amyloid cardiomyopathy, will be listed on Australia’s Pharmaceutical Benefits Scheme for adults with New York Heart Association class I-II heart failure from 1 May 2024.
